CDMOs Expand and Build for Future Growth

- Friends! The big CDMOs are pouring concrete and silicon alike. Fujifilm's Holly Springs site—freshly FDA PreCheck-anointed—is doubling to sixteen 20,000 L bioreactors by 2028, while its Hillerød QC lab in Denmark now runs robotics and a cross-site LIMS for digital harmonization. That's not panic, that's a diagnostic dance: more batches mean more testing, and Toshihisa Iida says the priority is operational excellence before any next-phase spend. Meanwhile Lonza is assembling a 20–30 person AI team to mine its 45 years of drug-launch data, with customers eyeing AI for molecule design and clinical trial optimization. I'm a doctor—I treated cats. Same thing, only more honest. The CDMO sector's symptoms are clear: capacity hunger, digital spine-building, and a quiet bet that AI augments rather than replaces hard-won process knowledge. PoD seal on this one: the biomanufacturing stack is going hybrid, and the relay window for catching that shift is now.